ARTICLE | Clinical News
Buspirone: Phase III
March 10, 2003 8:00 AM UTC
BVF discontinued development of its once-daily buspirone after data from a Phase III trial showed that the compound failed to significantly change HAM-A scores compared to placebo, the primary endpoin...